CHI3L1 and neoplasm: They also provide significant therapeutic implications because simultaneous targeting of CHI3L1 and CTLA-4 using monoclonal antibodies in combination generate, at least additive, antitumor responses in vivo and induction of synergistic tumor cell death and CD8+ cytotoxic T lymphocyte differentiation with bispecific antibodies that simultaneously target CHI3L1 and CTLA-4.